AdaptHealth (AHCO) Q4 2025 earnings review
Capitated Growth Ramp Costs Upfront Margins
AdaptHealth is aggressively transitioning its business model toward massive capitated contracts, and the growing pains are visible. While revenue accelerated sequentially throughout 2025 to reach $846.3M in Q4, net income collapsed into a $102.8M loss. This reversal was driven by heavy upfront infrastructure spending ($10M+) for its new IDN capitated contract, a $14.5M legal settlement, and a painful $128M goodwill impairment in the struggling Diabetes segment. Despite the margin hit, cash generation remains a bright spot—the company spun out $219.4M in Free Cash Flow for the year and paid down $250M in debt, earning credit upgrades from both S&P and Moody's. The FY26 guidance indicates these investments will pay off, projecting a return to solid top-line and EBITDA growth.
🐂 Bull Case
Despite GAAP losses, operating cash flow jumped to $601.8M for the year. The company beat its own Free Cash Flow guidance, generating $219.4M and retiring $250M in debt.
The company successfully onboarded nearly 500 dedicated employees and expanded into Hawaii to secure start dates for its landmark IDN capitated contract. This guarantees a highly predictable, sticky revenue stream for 2026.
🐻 Bear Case
Management spent the first three quarters of 2025 teasing a turnaround in the Diabetes Health segment. The Q4 reality check was a $128M non-cash goodwill impairment charge, acknowledging the asset's fair value has permanently dropped.
Adjusted EBITDA fell 18.7% YoY in Q4. Growth is proving expensive—over $10M in strategic investments were required just to launch the new capitated contract, compressing near-term profitability.
⚖️ Verdict: ⚪
Neutral. The company is successfully executing its strategic pivot to value-based care and cleaning up its balance sheet, but the massive impairment in Diabetes and heavy upfront costs for new contracts show that the operational transition remains messy.
Key Themes
Aggressive Deleveraging Strategy Paying Off
Debt reduction has been management's top capital allocation priority, and they delivered. The company paid down $25M in Q4, bringing the full-year total to $250M. This aggressive deleveraging lowered interest expense to $105.7M (down from $126.6M in FY24) and earned the company formal credit rating upgrades from both S&P and Moody's. The balance sheet is officially derisked.
The Diabetes Health Segment Reality Check
Throughout early 2025, management cited 'sequential improvement' and 'promising signs' in the Diabetes segment. Q4 completely reversed this positive narrative. The company recorded a $128M goodwill impairment charge specifically tied to the Diabetes unit, signaling that the structural headwinds (commercial payer pressure and potential pharmacy channel shifts) have inflicted permanent damage to the unit's valuation.
Tech Innovation: Digital Engagement Scaling Rapidly
AdaptHealth is successfully digitizing its patient relationships. The 'myApp' platform more than doubled its active user base, growing from 118,000 users in 24Q3 to 327,300 users in 25Q4. This self-service capability directly reduces call center volume and lowers the cost to serve, providing crucial operating leverage as the company scales its patient census.
Growth is Cannibalizing Near-Term Margins
The highly anticipated multi-billion-dollar IDN capitated contract is now live, but onboarding it was expensive. Q4 margins were battered by over $10M in 'strategic investments' to secure the start dates, including hiring 500 dedicated employees. While this revenue will eventually ramp up, it confirms that winning massive value-based contracts requires brutal upfront capital and labor expenditures.
Legal Headwinds Resurface
In addition to operational investments, Q4 earnings were suppressed by a $14.5M legal settlement expense. While flagged as non-recurring, this cash outflow slightly dampened the otherwise stellar cash flow generation story for the quarter.
Other KPIs
Accelerating. Up from $541.8M in FY24. This highlights the underlying health of the core business; despite a massive GAAP net loss caused by non-cash impairments, the actual cash generated by operations continues to expand robustly.
Accelerating. Up significantly from $306.1M in FY24. This massive step-up in equipment purchases reflects the heavy infrastructure and vehicle procurement required to build out the network for the new multi-million-life capitated contracts.
Guidance
Accelerating. The midpoint of $3.475 billion implies a 7.1% YoY growth rate, a massive reversal from the 0.5% contraction seen in FY25. This proves management expects the new IDN capitated contract to fully offset the headwinds previously seen in Sleep and Diabetes.
Accelerating. The midpoint of $705 million implies 14.3% YoY growth compared to the depressed $616.7M print in FY25. Management expects to regain operating leverage as the upfront labor and location investments from late 2025 begin to generate fully scaled revenue.
Stable to slightly Decelerating. The midpoint of $200 million is slightly below the FY25 achievement of $219.4M. This indicates that while earnings are expected to grow, heavy capital expenditures will still be required throughout 2026 to support patient setup demands for the new contracts.
Key Questions
Diabetes Segment Future
Given the $128M goodwill impairment charge this quarter, has your strategic view on the Diabetes Health segment changed? Is this asset still considered core to the 'One Adapt' strategy, or is it a candidate for divestiture?
Capitated Margin Trajectory
You absorbed over $10M in strategic investments in Q4 to launch the new IDN contract. At what point in FY26 do you expect this specific contract to reach enterprise-average EBITDA margins?
Capital Allocation Shift
With the net leverage ratio dropping rapidly and credit agencies upgrading your debt, will FY26 capital allocation shift away from aggressive debt paydown toward share repurchases or M&A?